PVLAPalvella Therapeutics, Inc.Running, no new patients
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Microcystic Lymphatic Malformation
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 51 (final count)
- Started
- Jul 31, 2024
- Main results expected
- Jan 14, 2026
- Fully finished
- Jul 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall microcystic lymphatic malformations Investigator Global Assessment (mLM-IGA)
Measured over: At Week 24
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06239480 · record last updated 2026-03-27 · checked 2026-11-09 15:47 UTC